Aberrant expression of NDC80 has been reported in several other tumors [35–39], for instance osteosarcoma, hepatocellulcar carcinoma, colorectal cancer and breast cancer, indicating its potential as a newly bio target. This evidence concerns the gene NDC80 and colorectal cancer.